Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hlusi

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical Laboratory|February 7, 2017
Validation of a New Panel of Automated Chemiluminescence Assays for Anticardiolipin Antibodies in the Screening for Antiphospholipid SyndromeD Janek, L Slavik, J Ulehlova, et al.
Neoplasma|March 15, 2018
Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single centerM Palova, T Szotkowski, A Hlusi, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 17, 2019
Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and ApixabanL Slavik, J Jacova, D Friedecky, et al.
Clinical Laboratory|October 9, 2014
Detection of clopidogrel resistance using ADP induced aggregometry with specific inhibitor PGE1L Slavik, J Ulehlova, V Krcova, et al.
Clinical Laboratory|October 2, 2018
Thrombin Generation Testing in Patients with MyelofibrosisM Palova, L Slavik, A Hlusi, et al.
Clinical Laboratory|September 5, 2014
The advantages and limitations of impedance aggregometry in detection of heparin-induced thrombocytopeniaL Slavik, G Svobodova, J Ulehlova, et al.
Oncogene|April 11, 2019
Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferationJ Stetka, P Vyhlidalova, L Lanikova, et al.
Vnitrni Lekarstvi|September 11, 2008
[What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine]M Penka, J Schwarz, T Pavlík, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical Laboratory|February 7, 2017
Validation of a New Panel of Automated Chemiluminescence Assays for Anticardiolipin Antibodies in the Screening for Antiphospholipid SyndromeD Janek, L Slavik, J Ulehlova, et al.
Neoplasma|March 15, 2018
Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single centerM Palova, T Szotkowski, A Hlusi, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 17, 2019
Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and ApixabanL Slavik, J Jacova, D Friedecky, et al.
Clinical Laboratory|October 9, 2014
Detection of clopidogrel resistance using ADP induced aggregometry with specific inhibitor PGE1L Slavik, J Ulehlova, V Krcova, et al.
Clinical Laboratory|October 2, 2018
Thrombin Generation Testing in Patients with MyelofibrosisM Palova, L Slavik, A Hlusi, et al.
Clinical Laboratory|September 5, 2014
The advantages and limitations of impedance aggregometry in detection of heparin-induced thrombocytopeniaL Slavik, G Svobodova, J Ulehlova, et al.
Oncogene|April 11, 2019
Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferationJ Stetka, P Vyhlidalova, L Lanikova, et al.
Vnitrni Lekarstvi|September 11, 2008
[What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine]M Penka, J Schwarz, T Pavlík, et al.
Pageof 1